Mitoxantrone

Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 µM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively. It is an anthracenedione (not an anthracycline) antineoplastic agent. It disrupts DNA synthesis and DNA repair in both healthy cells and cancer cells. It is used in the treatment of certain types of cancer, mostly metastatic breast cancer, acute myeloid leukemia, and non-Hodgkin’s lymphoma. It was also shown to improve the survival of children suffering from first relapse of acute lymphoblastic leukaemia. It also engages in intercalation.